Metrics as of 10/13/2026, 06:43 PM (Berlin time), refresh in progress.
Celldex Therapeutics Stock
Celldex Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Anthony S. Marucci
- Employees
- 198
- Market cap
- $1.9 B
- IPO
- 15/05/1986
Celldex Therapeutics, Inc. is a biopharmaceutical company in the Healthcare sector, operating within the Biotechnology industry. Headquartered in Hampton, US, the company focuses on developing antibody-based treatments, specifically monoclonal and bispecific antibodies for a range of diseases. Their pipeline features…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Celldex Therapeutics stock: price history
1D
-3.2%
1W
-8.2%
1M
-22.8%
6M
-14.6%
YTD
+4.9%
1Y
+5.0%
2Y
-9.1%
5Y
-47.4%
10Y
-44.8%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~1% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Celldex Therapeutics
Analyst assessment of Celldex Therapeutics
PRICE TARGET LOW
US$45.00
CONSENSUS
US$66.80
MEDIAN
US$62.50
PRICE TARGET HIGH
US$100.00
0
STRONG BUY
16
BUY
4
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 02/10/2026
Celldex Therapeutics stock metrics
P/E
-6.53
P/B
3.1
EV/EBITDA
-6.24
RETURN ON EQUITY
-10.3%
NET MARGIN
-334,104.5%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.2%
FLOAT SHARES
61,336,644
AVG. DAILY VOLUME (30D)
1,814,458
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Celldex Therapeutics stock
What does Celldex Therapeutics do?
Celldex Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Anthony S. Marucci, the company employs around 198 people.
The IPO was on 15/05/1986; the stock trades on NASDAQ under the ticker CLDX.
What do analysts say about Celldex Therapeutics stock?
20 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$66.80, ranging from US$45.00 to US$100.00, with a median of US$62.50.
This is an external assessment, not a statement by Market Jury.
When does Celldex Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 1% stronger than usual.
Does Celldex Therapeutics pay a dividend?
No, Celldex Therapeutics currently does not pay a dividend.
Which stocks are comparable to Celldex Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Celldex Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Celldex Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.